ALKS Alkermes plc
$45.83
Alkermes plc (ALKS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Insider signal
In line
Selling ran in line with ALKS's own trailing one-year pace, with 72% of sale value under a prearranged plan.
Cluster activity
0 buyers in the last 30 days
0 buyers in the last 90 days
4 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
7
33 transactions
Purchases
$0
0 shares
Sales
$10.5M
267,375 shares
Net activity
-$10.5M
purchases less sales
How much of that selling was preplanned? 72% planned / 28% discretionary
10b5-1 plan sales
$7.6M
31 transactions · 206,686 shares
Discretionary sales
$2.9M
2 transactions · 60,689 shares
Largest single sale: $2.2M.
Where they traded
Buy
Sell
Dot area is proportional to transaction value.
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell 10b5-1 | 2,034 | $48.01 | $97.7K | 223,422 −0.9% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $46.99 | $422.9K | 65,389 −12.1% of holding | |
| Nichols Christian Todd 2 fills | SVP, Chief Commercial Officer | Sell 10b5-1 | 7,576 | $49.23 | $372.9K | 102,857 −6.9% of holding | |
| snyderman nancy lynn MD | Director | Sell | 44,472 | $50.35 | $2.2M | 15,395 −74.3% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $48.58 | $437.2K | 69,389 −11.5% of holding | |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell 10b5-1 | 2,034 | $48.58 | $98.8K | 225,456 −0.9% of holding | |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell 10b5-1 | 2,034 | $54.03 | $109.9K | 227,490 −0.9% of holding | |
| Hopkinson Craig C. 2 fills | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $51.51 | $463.6K | 74,089 −10.8% of holding | |
| Wright Christopher I | Director | Sell 10b5-1 | 2,000 | $45.10 | $90.2K | 25,680 −7.2% of holding | |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell 10b5-1 | 2,034 | $43.05 | $87.6K | 229,524 −0.9% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $41.67 | $375.0K | 77,389 −10.4% of holding | |
| Parisi Samuel Joseph | VP, Finance (Interim PAO) | Sell | 16,217 | $42.36 | $687.0K | 7,717 −67.8% of holding | |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell 10b5-1 | 2,034 | $33.20 | $67.5K | 231,558 −0.9% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $33.40 | $300.6K | 81,389 −10% of holding | |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell 10b5-1 | 2,034 | $34.57 | $70.3K | 233,592 −0.9% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $35.51 | $319.6K | 85,389 −9.5% of holding | |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell 10b5-1 | 2,034 | $29.76 | $60.5K | 235,626 −0.9% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $29.72 | $267.5K | 89,389 −9.1% of holding | |
| Parisi Samuel Joseph | VP, Finance (Interim PAO) | Sell 10b5-1 | 6,890 | $29.29 | $201.8K | 7,717 −47.2% of holding | |
| Nichols Christian Todd | SVP, Chief Commercial Officer | Sell 10b5-1 | 6,000 | $30.00 | $180.0K | 109,769 −5.2% of holding | |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell 10b5-1 | 2,034 | $29.29 | $59.6K | 237,660 −0.8% of holding | |
| Cooke Shane 2 fills | Director | Sell 10b5-1 | 61,200 | $34.57 | $2.1M | 135,857 −31.1% of holding | |
| Hopkinson Craig C. 2 fills | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $33.93 | $305.4K | 61,740 −12.7% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 5,000 | $30.00 | $150.0K | 61,740 −7.5% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 4,000 | $28.00 | $112.0K | 61,740 −6.1% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 3,748 | $30.00 | $112.4K | 65,740 −5.4% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 4,000 | $29.30 | $117.2K | 65,740 −5.7% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $30.38 | $273.4K | 69,740 −11.4% of holding | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell 10b5-1 | 9,000 | $31.53 | $283.8K | 73,740 −10.9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.